FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2008
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

SOON SHIONG PATRICK 		2. Issuer Name and Ticker or Trading Symbol

Abraxis BioScience, Inc. [ ABBI ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      __ X __ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
Chairman and CEO
(Last)          (First)          (Middle)

C/O ABRAXIS BIOSCIENCE, INC. 11755, WILSHIRE BLVD., 20TH FLOOR 		3. Date of Earliest Transaction (MM/DD/YYYY)

1/12/2007
(Street)

LOS ANGELES, CA 90025
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   1/12/2007     J (1)    282986   D   (1) 3286611   I   By RSU Plan LLC   (4)
Common Stock   4/20/2007     J (2)    106119   D   (2) 3158628   I   By RSU Plan LLC   (4)
Common Stock   10/26/2007     J (3)    19258   D   (3) 3139370   I   By RSU Plan LLC   (4)
Common Stock   10/26/2007     J (3)    631015   D   (3) 115616590   I   By Family Trusts   (5)
Common Stock   10/26/2007     J (3)    68748   D   (3) 12586061   I   By GRATs   (6)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
( 1)  Contribution to the issuer of shares in connection with vesting of certain restricted units held by an employee or consultant of the issuer. The closing price on the date of contribution was $26.79.
( 2)  Contribution to the issuer of shares in connection with vesting of certain restricted units held by an employee or consultant of the issuer. The closing price on the date of contribution was $27.67.
( 3)  Surrender of shares pursuant to an escrow agreement entered into April 18, 2006 in connection with merger of American BioScience Inc. with and into the issuer (the "Merger"). The shares were surrendered in satisfaction of claims arising from the indemnification obligation set forth in the merger agreement. The closing price on the date of surrender was $24.27.
( 4)  LLC has agreed to contribute to the issuer from time to time, in connection with vesting of certain restricted units held by certain employees of the issuer, up to the total number of shares held by LLC (or, at the election of the LLC, cash in an amount equal to the value of the shares otherwise required to be contributed by the LLC). The Reporting Person disclaims beneficial ownership of the shares held by the LLC except to the extent of his pecuniary interest in the LLC.
( 5)  Includes shares acquired by the family trusts for the benefit of members of the Reporting Person's immediate family. The Reporting Person disclaims beneficial ownership of the shares held by the family trusts except to the extent of his pecuniary interest therein.
( 6)  Includes shares acquired by the GRATS for the benefit of members for the benefit of members of the Reporting Person's immediate family. The Reporting Person disclaims beneficial ownership of the shares held by the family trusts except to the extent of his pecuniary interest therein.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
SOON SHIONG PATRICK
C/O ABRAXIS BIOSCIENCE, INC. 11755
WILSHIRE BLVD., 20TH FLOOR
LOS ANGELES, CA 90025 		X X Chairman and CEO

Signatures
/s/ Richard Maroun, power of attorney 10/30/2007
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Abraxis Bioscience (MM) (NASDAQ:ABBI)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024 Click aqui para mais gráficos Abraxis Bioscience (MM).
Abraxis Bioscience (MM) (NASDAQ:ABBI)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024 Click aqui para mais gráficos Abraxis Bioscience (MM).